Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Free Cash Flow: 2018-2024

Historic Free Cash Flow for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to -$307.9 million.

  • Avidity Biosciences' Free Cash Flow fell 133.05% to -$156.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$592.3 million, marking a year-over-year decrease of 214.18%. This contributed to the annual value of -$307.9 million for FY2024, which is 149.76% down from last year.
  • According to the latest figures from FY2024, Avidity Biosciences' Free Cash Flow is -$307.9 million, which was down 149.76% from -$123.3 million recorded in FY2023.
  • Avidity Biosciences' Free Cash Flow's 5-year high stood at -$38.2 million during FY2020, with a 5-year trough of -$307.9 million in FY2024.
  • Its 3-year average for Free Cash Flow is -$190.1 million, with a median of -$139.1 million in 2022.
  • As far as peak fluctuations go, Avidity Biosciences' Free Cash Flow tumbled by 1,794.41% in 2020, and later increased by 11.36% in 2023.
  • Over the past 5 years, Avidity Biosciences' Free Cash Flow (Yearly) stood at -$38.2 million in 2020, then slumped by 157.93% to -$98.6 million in 2021, then slumped by 41.13% to -$139.1 million in 2022, then rose by 11.36% to -$123.3 million in 2023, then crashed by 149.76% to -$307.9 million in 2024.